This list of the top 5 best selling biologics of 2012 just goes to show the success that some biologics are experiencing in the pharma market – but is it all plain sailing ahead for the biologic manufacturers? Biosimilars have the potential to reduce treatment costs and increase accessibility of treatments to populations not able to afford their branded counterparts, and here I thought I'd look at some biosimilars which could be closest to threatening these best-selling branded biologics in the future.
Humira (adalimumab) – (AbbVie – 2012 sales: $9.265 billion)
Boehringer Ingelheim: Completed Phase I trial with BI695501 last year
Remicade (infliximab) – (Johnson & Johnson and Merck & Co – 2012 sales: $8.215 billion)
Celltrion: CT-P13 in Phase III clinical trials in South Korea and UK
Enbrel (etanercept) (Amgen and Pfizer – 2012 sales: $7.963 billion)
Mycenax Biotech: TuNEX is in Phase III clinical trials in Japan and South Korea
Hanwha Chemical: HD203 is in Phase III clinical trials in South Korea
Rituxan/MabThera (rituximab) – (Roche – 2012 sales: $7.285 billion)
Dr Reddy's Laboratories: Reditux marketed in Bolivia, Chile, Peru and India
Probiomed: Kikuzubam marketed in Bolivia, Chile, Peru and India
Boehringer Ingelheim: Recruiting participants for Phase III trials with BI695500 biosimilar
Herceptin (trastuzumab) – (Roche – 2012 sales: $6.397 billion)
Amgen/Actavis: Plans to progress its biosimilar Herceptin into Phase III trials during 2nd quarter of 2013.
Pfizer: Completed Phase I trial with PF-05280014
Are there any particularly important biosimilars you think I've missed of the list? Why not join our discussion on LinkedIn, or leave a comment below.
If you want to know more about biosimilars, you might be interested in attending the World Biosimilar Congress 2013, 12-13 November 2013, which brings together buyers and sellers from across the biosimilar and biobetter industry.
Want more from Total BioPharma? Sign up to our newsletter – it doesn't cost anything and only takes a minute.